Allergic conjunctivitis, especially inflammation of the conjunctiva associated with hay fever and the reaction to pollen allergens.
Composition:
1 ml eye drops contain 0.5 mg antazoline hydrochloride and 0.4 mg tetryzoline hydrochloride.
Action:
Preparation containing antazoline - antihistamine and tetryzoline - a sympathomimetic drug. Antazoline is a selective antagonist of H-receptors1, effectively relieves pruritus. Tetryzolina is an α-adrenomimetic, reduces redness and swelling in allergic conjunctivitis.
Contraindications:
Hypersensitivity to antazoline hydrochloride, tetryzoline or auxiliary substances. Concomitant use of MAO inhibitors.
Precautions:
Sympathomimetic drugs should be used with caution in patients with diabetes mellitus, hypertension, hyperthyroidism and increased thyroid hormone levels, arrhythmias or tachycardia and adrenal pheochromocytoma. The preparation should be used with caution in elderly patients with severe cardiovascular disease, including arrhythmia, poorly controlled hypertension or diabetes mellitus. Caution should be exercised in patients with risk factors or with a diagnosis of angle-closure glaucoma, unless a cut-out (or incision) of the iris has been made. Overuse of vasoconstrictor drugs may cause relapse of hyperemia after discontinuation. Do not use the drug in patients with dry eye syndrome who have not previously consulted a doctor. Patients with symptoms of eye dryness should stop using the medicine and see a doctor. The use of the preparation may mask the eye infection. Do not use in children under 2 years. Children over 2 years should be cautious.
Pregnancy and lactation:
No clinical data on use during pregnancy - the product should only be used if the benefits outweigh the risks to the fetus or child. It is not known if the active substances are excreted in breast milk - caution should be exercised when breast-feeding.
Side effects:
Transient feelings of burning or stinging in the eye were most commonly observed. In addition, there may be: signs and symptoms of local allergic reaction, dispersion of iris pigment, mydriasis, blurred vision, acute or chronic conjunctivitis, toxic conjunctival papules, dry eye, relapse after treatment, reperfusion, glaucoma angle. The following may occur: headache and dizziness, drowsiness, tremor, agitation, coronary angina, hypertension, tachycardia, increased sweating, and very rarely hypersensitivity reactions.
Dosage:
Adults and adolescents: 1 drop into the conjunctival sac 2-3 times a day for 14 days. Children over 2 years: no studies on this group of patients; due to possible general actions, caution should be exercised and dosage should be limited to 1-2 drops per day. After instillation, the nasolacrimal duct should be blocked or the eyes closed for 3 minutes to reduce the systemic absorption of the preparation. This may reduce systemic side effects and increase the local activity of the drug. Correct nasal-lacrimal duct obstruction is particularly important in patients with dry nasal congestion to prevent the nasal mucosa from entering the nasal mucosa. Patients should seek medical advice if the symptoms last longer than 3-4 days, worsen or if eye aches and blurred vision occur during treatment with the preparation. If the patient uses more than one eye medicine, each of these medicines should be given at least 5 minutes apart.
(C)
